Key result
Small molecular allosteric enhancers of GC-A enhanced ANP or BNP effects in cellular systems and ANP-induced vasorelaxation in rat aortic rings via a novel allosteric binding site.
Why the study?
Targeting GC-A has been limited to peptides, prompting efforts to develop small molecular activators of GC-A to enable oral administration and longer half-life.
Population
QBIHEK293A cells expressing GC-A, GC-B, or chimerae and aortic rings from Wistar rats
Comparison
Small molecular activators of GC-A vs controls
Design
Preclinical in vitro and ex vivo laboratory study
Authors
Loading...
Should not yet change practice; leaves open oral GC-A enhancement as a new cardiovascular strategy.
The discovery of novel small molecule allosteric enhancers of GC-A provides a new pharmacological tool and potential therapeutic strategy for cardiovascular diseases by potentiating endogenous ANP and BNP effects.
Andresen et al. (2023) studied this question. Small molecular allosteric enhancers of GC-A was evaluated on Enhancement of ANP or BNP effects in cellular systems and ANP-induced vasorelaxation in rat aortic rings. Small molecular allosteric enhancers of GC-A enhanced ANP or BNP effects in cellular systems and ANP-induced vasorelaxation in rat aortic rings via a novel allosteric binding site.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: